New Customers Get 10% Off – Use Code: LUX10

Growth Factor Analog Peptide

IGF-1 LR3

5.0 Reviews

CAS: 143045-27-6Long Arginine 3-IGF-1Long R3 IGF-1LR3-IGF-1

An 83-amino acid synthetic analog of IGF-1 with lower binding protein affinity and a longer half-life, researched for its anabolic and tissue growth potential in preclinical studies. Premium Research Peptide.

Original price was: $94.99.Current price is: $85.49.

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How IGF-1 LR3 Works

The Science, Simplified

IGF-1 Receptor Activation & Hyperplasia

IGF-1 LR3 (Long Arginine 3-IGF-1) is a synthetic analog of human insulin-like growth factor 1. It binds to the IGF-1 receptor (IGF-1R), triggering a potent anabolic signaling cascade.
Key insight: In research models, IGF-1 LR3 is uniquely associated with hyperplasia (the splitting of muscle cells to create new fibers) in addition to hypertrophy (increasing the size of existing cells), leading to potentially more permanent tissue growth.
GE
Primary

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

COL
Strongest

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Cu²⁺
Supportive

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

CReduced IGFBP Binding Affinity

Native IGF-1 is rapidly neutralized by IGF-binding proteins (IGFBPs). IGF-1 LR3 features an amino acid substitution at position 3 and a 13-amino acid N-terminal extension.

Key insight: These structural modifications reduce its affinity for IGFBPs by up to 1,000-fold, allowing more of the peptide to remain in its “free” active state to interact with cellular receptors.

Extended Biological Half-Life

Because it avoids binding to inhibitory proteins, IGF-1 LR3 remains active in the system significantly longer than standard IGF-1.

Key insight: While native IGF-1 has a half-life of roughly 10–20 minutes, IGF-1 LR3 maintains a biological half-life of 20–30 hours, allowing for sustained anabolic signaling with less frequent administration in research protocols.

Wrinkle Reduction Comparison

Safety Profile from Research

What clinical studies report

GF-1 LR3 is a powerful growth factor analog; research protocols typically focus on monitoring glycemic levels and systemic growth markers.

🧿 Common Digestive Issues

15%

Hypoglycemia

mild

10%

Lethargy

mild

12%

Muscle Pump/Tightness

mild

Safety Advantage

Potency & Efficiency

Because these peptides work on existing biological pathways rather than forcing a synthetic response, they maintain a high safety margin.
  • Lower Dosage Requirements: Due to its extended half-life and free-state availability, researchers can achieve biological markers with significantly lower doses than native IGF-1.
  • Targeted Anabolic Response: Research indicates a high specificity for skeletal muscle and connective tissue growth in animal models.
  • No HPTA Suppression: Unlike anabolic steroids, IGF-1 LR3 does not suppress natural testosterone production.

📊 Discontinuation Rates

🚫 Trial Exclusions

⚡ Regulatory Status

💡 Researcher Notes

Compound Information

Technical specifications for each component

🔬 Molecular Profile

What Is IGF-1 LR3?

CAS Number

143045-27-6

Molecular Weight

9,117.60 g/mol

Amino Acids

83

Formula

C400H625N111O115S9

Sequence

MFPAMPLSSL FVNGPRTLCG...

PubChem Databases

🧊 Storage Requirements

How It Differs from Native IGF-1

N-terminal extension

+13 amino acids (MFPAMPLLSLFVN)

Position 3 substitution

Glu → Arg

Total length

83 vs 70 amino acids

IGFBP affinity

Dramatically reduced

IGF-1R affinity

Retained

📋 Research Status

Where Each Stands

Classification

Investigational Peptide / Growth Factor

WADA Status

Strictly Prohibited (S2 category)

IGF-1 LR3 studies

400+ publications

IGF-1 class

10,000+ publications

PubMed Search

Frequently Asked Questions

Common questions about IGF-1 LR3

IGF-1 LR3 is a synthetic, long-acting analog of human insulin-like growth factor 1. It was engineered to overcome the limitations of natural IGF-1, specifically its short half-life and tendency to be deactivated by binding proteins.
The "LR3" stands for "Long Arginine 3." The extension and amino acid change prevent the peptide from being bound and deactivated by IGFBPs. This keeps the peptide "free" and active in the system for nearly 24 hours, compared to minutes for standard IGF-1.
Most anabolic agents cause hypertrophy (existing muscle cells getting bigger). IGF-1 LR3 is researched for its ability to induce hyperplasia, which is the creation of brand-new muscle fiber cells, potentially leading to a higher ceiling for muscle growth.
No. While native IGF-1 (Mecasermin) is approved for specific growth disorders, the LR3 analog is currently an investigational compound and is sold strictly for laboratory research and in-vitro evaluation.
It is extremely sensitive to temperature and agitation. It should be reconstituted gently (never shaken) and kept refrigerated at all times once in liquid form. Researchers often use a mild acidic solution (like 0.1% acetic acid) for reconstitution to ensure long-term stability in the vial.

Sources & References

Peer-reviewed research

Biochemical Journal

Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats

1992

Tomas FM, Knowles SE, Owens PC et al.

View Source

Journal of Endocrinology

Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when

1996

Tomas FM, Lemmey AB, Read LC

View Source

Journal of Endocrinology

IGF-binding proteins are multifunctional and act via IGF-dependent and -independent

2002

Mohan S, Baylink DJ

View Source

American Journal of Pathology

IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype

2011

von der Thüsen JH, Borensztajn KS, Moimas S et al.

View Source

Journal of Endocrinology

Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig

1995

Conlon MA, Tomas FM, Owens PC et al.

View Source
  • Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

My Account
Follow Us
Linkedin X-twitter Icon-instagram-1 Facebook-square